Health Innovation
Skin Repair and Wound Healing: 5 Startups to Watch in 2026
DealBio follows early-stage startups working across skin protection, wound management and tissue repair. These five companies show distinct approaches, from daily protection of sensitive skin to cell-based reconstruction.
- Wound Care
- Dermatology
- Medical Devices
- Biotech
Damaged or fragile skin creates very different needs. Protective fabrics can reduce friction on sensitive skin; deep wounds require dressings that reach irregular spaces; difficult wounds require technologies suited to distinct repair needs.
The opportunity spans materials, wound-care devices and regenerative medicine. These startups are connected by specific use cases rather than a single shared treatment mechanism.
At a Glance
- AleSacDenmark2026Injectable antimicrobial wound foam
- Deuxième PeauFrance2024Textiles for eczema-prone and fragile skin
- Ingenskin TherapeuticsFrance2026Personalised skin-graft development
- BioelectrixSweden2025Electrical wound electrodes
- ChainPeptidesFinland2022Antimicrobial peptides and smart plaster
01
AleSac
Developing antimicrobial foam dressings that fill deep, complex wounds
- Country
Denmark- Founded
- 2026
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why AleSac stands out
AleSac combines academic polymer research with product engineering for difficult wound spaces. The company has developed a prototype dispenser and reports laboratory antimicrobial performance against multidrug-resistant bacteria. It completed DTU Science Park's MedTech Growth accelerator and joined US BioLab CATALYST, with engineering support from Creadis.
What AleSac is building
Its injectable silicone foam expands to fill irregular wound cavities, absorbs wound fluid and has antimicrobial properties. The proposed applications include protection during combat-wound evacuation and chronic-wound dressings.
Making protective textile sleeves for eczema-prone and fragile skin
- Country
France- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why Deuxième Peau stands out
Deuxième Peau addresses the everyday challenges of clothing friction on inflamed and sensitive skin. The company has a commercial protective-textile offering and combines textile design with a dermatology-focused application.
What Deuxième Peau is building
Its washable protective textile sleeves and garments form a comfortable layer between skin and external surfaces. This approach is aimed at protecting fragile skin and supporting comfort.
Developing personalised skin grafts from patients' own cells
- Country
- France
- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Ingenskin Therapeutics stands out
Ingenskin Therapeutics focuses on patient-specific tissue reconstruction, with preclinical validation and exclusive intellectual-property signals supporting its development programme. Its cell-based approach adds a regenerative-medicine perspective to this group.
What Ingenskin Therapeutics is building
The company is developing personalised grafts from patients' own cells for reconstructive skin applications. Tissue engineering combines cells and supporting methods to form living tissue.
Developing electrical wound electrodes to accelerate healing of diabetic foot ulcers
- Country
Sweden- Founded
- 2025
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why Bioelectrix stands out
Research co-authored by Bioelectrix founders observed nearly threefold faster closure of wound gaps in laboratory skin-cell models with electrical stimulation. The company has filed an international wound-dressing patent application and received backing from Chalmers Ventures.
What Bioelectrix is building
The startup is developing electrodes that deliver controlled direct current to guide skin-cell migration in difficult wounds, initially diabetic foot ulcers. Sensing capabilities are part of the development roadmap.
Developing antimicrobial smart plasters for diabetic foot ulcers
- Country
- Finland
- Founded
- 2022
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why ChainPeptides stands out
ChainPeptides reports granted patents covering three antimicrobial peptides across multiple jurisdictions and laboratory activity against several bacterial groups. Its founder has scientific expertise in antimicrobial-peptide development; OYSTER Incubator has supported the company.
What ChainPeptides is building
The planned smart plaster combines antimicrobial peptides with infection sensing for diabetic foot ulcers. Peptides are short chains of amino acids; antimicrobial peptides are designed to act against microorganisms.